Stockreport

Vir surges on up to $1.7B deal with Astellas to advance prostate cancer asset [Seeking Alpha]

ASTELLAS PHARMA UNSP/ADR  (ALPMY) 
NASDAQ:AMEX Investor Relations: astellas.com/jp/en/investors
PDF development and commercialization deal with Astellas Pharma ( ALPMF ) for the CD3 T-cell engager VIR-5500 for metastatic castration-resistant prostate cancer. Terms ca [Read more]